Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 1, 1999, Pages 39-48

  Pollard, Richard B ^a   Peterson, Dolores ^b   Hardy, David ^c   Pottage, John ^d   Murphy, Robert L ^e   Gathe, Joseph ^f   Beall, Gildon ^g   Rutkievicz, Victoria ^h   Reynolds, Laurie ^h   Cross, Anne P ^h   Dunkle, Lisa M ^h  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f Park Plaza Medical Center ^*  (United States)

^g HARBOR UCLA MEDICAL CENTER   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiretroviral therapy; Didanosine; Drug therapy, combination; Stavudine

Indexed keywords

DIDANOSINE; STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 0344980382     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199909010-00005     Document Type: Article

References (27)

1. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
2. Katzenstein DA, Hammer SM, Hughes DM, et al. The relation of virologie and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
3. Cooper DA, Katlama C, Montaner J, Corlis PJ. Randomized trial of addition of lamivudine or lamivudine plus loviride in zidovudine-containing regimens for patients with HIV-1 infection: the CAESER trial. Lancet 1997;349:1413-21.
4. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-9.
5. Deminie CA, Bechtold MC, Stock D, et al. Evaluations of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother 1996;40:1346-51.
6. Gao W-Y, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993;91:2326-33.
7. Richman DD. Clinical significance of drug resistance in human immunodeficiency virus. Clin Infect Dis 1995;21(Suppl 2): S166-9.
8. D'Aquila RT. HIV-1 chemotherapy and drug resistance. Clin Diag Virol 1995;3:299-316.
9. Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1993;37:2231-4.
10. Lin PF, Samanta H, Rose RE, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994;170: 1157-64.
11. Yarchoan R, Broder S. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. N Engl J Med 1987;316:557-64.
12. Seifert RD, Stewart MB, Sramek JJ, Conrad J, Kaul S, Cutter NR. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol 1994;38: 405-10.
13. Rozencweig M, McLaren C, Beltangady J, et al. Overview of the phase I trials of 2′,3′-dideoxyinosine (ddI) conducted on adult patients. Rev Infect Dis 1990;12(Suppl 5):S570-5.
14. Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis 1995;171(Suppl 2): S113-7.
15. Raffi F, Reliquet V, Auger S, et al. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients. AIDS 1998;12:1999-2005.
16. 3 and predominantly infected with HIV-1 clade E [abstract 12241]. Presented at the XII World AIDS Conference, Geneva, 1998.
17. Rutschmann OT, Opravil M, Iten A, et al. A placebo controlled trial of didanosine plus stavudine with and without hydroxyurea for HIV infection. AIDS 1998;12:F71-7.
18. Federici ME, Lupo S, Cahn P, et al. Hydroxyurea in combination regimens for the treatment of antiretroviral naïve, HIV-infected adults [abstract 12235]. Presented at the XII World AIDS Conference, Geneva, 1998.
19. Eron J, Peterson D, Murphy R, et al. An open-labeled randomized, comparative study of d4T + ddI + IDV versus ZDV + 3TC + IDV in treatment of naïve HIV-infected patients (Start II) [abstract 12225]. Presented at the XII World AIDS Conference, Geneva, 1998.
20. Molina JM, Journot V, Ferchal F, Pellegrin I, Rancinan C, Sombardier MN, Decazes JM. ALBI (ARNS 070): a randomized controlled trial to evaluate the efficacy and safety of AZT/3TC vs alternating d4T/ddI and AZT/3TC Vs d4T/ddI [abstract 12227]. Presented at the XII World AIDS Conference, Geneva, 1998.
21. Conrad AJ, Schmid P, Syndulko K, et al. Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:425-35.
22. Division of AIDS, National Institutes of Allergy and Infectious Diseases. ACTG virology manual for HIV laboratories. Bethesda, National Institutes of Health, 1994.
23. 3 [abstract 198]. Proceedings of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.
24. Katlama C, Valantin MA, Calvez V, et al. Efficacy and tolerability of stavudine plus lamivudine in treatment-naïve and treatment-experienced patients with HIV-1 infection. Ann Intern Med 1999; 129:525-31.
25. Foudraine N, De Wolf F, Hoetelmans R, Portegies P, Maas J, Lange J. CSF and serum HIV-RNA levels during AZT/3TC and d4T/3TC treatment [abstract LB5]. Proceedings of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997.
26. Coakley E, Gillis J, Pedneault L, Dunkle L, Hammer S. Susceptibilities of HIV-1 isolates derived from patients treated with didanosine and stavudine in combination. Antiviral Ther 1997; 2(Suppl 3):95-7.
27. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997; Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997;277: 1962-9.